SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity

Show simple item record

dc.contributor.author Richardson, Simone I.
dc.contributor.author Manamela, Nelia P.
dc.contributor.author Motsoeneng, Boitumelo M.
dc.contributor.author Kaldine, Haajira
dc.contributor.author Ayres, Frances
dc.contributor.author Makhado, Zanele
dc.contributor.author Mennen, Mathilda
dc.contributor.author Skelem, Sango
dc.contributor.author Williams, Noleen
dc.contributor.author Sullivan, Nancy J.
dc.contributor.author Misasi, John
dc.contributor.author Gray, Glenda G.
dc.contributor.author Bekker, Linda‑Gail
dc.contributor.author Ueckermann, Veronica
dc.contributor.author Rossouw, Theresa M.
dc.contributor.author Boswell, M.T.
dc.contributor.author Ntusi, Ntobeko A.B.
dc.contributor.author Burgers, Wendy A.
dc.contributor.author Moore, Penny L.
dc.date.accessioned 2023-05-12T12:08:55Z
dc.date.available 2023-05-12T12:08:55Z
dc.date.issued 2022-02-15
dc.description.abstract Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOCs) exhibit escape from neutralizing antibodies, causing concern about vaccine effectiveness. However, while non-neutralizing cytotoxic functions of antibodies are associated with improved disease outcome and vaccine protection, Fc effector function escape from VOCs is poorly defined. Furthermore, whether VOCs trigger Fc functions with altered specificity, as has been reported for neutralization, is unknown. Here, we demonstrate that the Beta VOC partially evades Fc effector activity in individuals infected with the original (D614G) variant. However, not all functions are equivalently affected, suggesting differential targeting by antibodies mediating distinct Fc functions. Furthermore, Beta and Delta infection trigger responses with significantly improved Fc cross-reactivity against global VOCs compared with D614G-infected or Ad26.COV2.S-vaccinated individuals. This suggests that, as for neutralization, the infecting spike sequence affects Fc effector function. These data have important implications for vaccine strategies that incorporate VOCs, suggesting these may induce broader Fc effector responses. en_US
dc.description.department Immunology en_US
dc.description.department Internal Medicine en_US
dc.description.librarian am2023 en_US
dc.description.sponsorship The EDCTP2 program of the European Union’s Horizon 2020 program, Wellcome Centre for Infectious Diseases Research in Africa, the SA-MRC, MRC UK, NRF, the Lily and Ernst Hausmann Trust, the South African Research Chairs Initiative of the Department of Science and Innovation and National Research Foundation of South Africa, the SA Medical Research Council SHIP program, the Center for the AIDS Program of Research (CAPRISA) and an L’Oreal/UNESCO Women in Science South Africa Young Talents award. en_US
dc.description.uri http://www.cell.com/cell-host-microbe/home en_US
dc.identifier.citation Richardson, S.I, Manamela, N.P., Motsoeneng, B.M. et al. 2022, 'SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity', Cell Reports Medicine, vol. 3, art. 100510, pp. 1-8, doi : 10.1016/j.xcrm.2022.100510. en_US
dc.identifier.issn 1931-3128 (print)
dc.identifier.issn 1934-6069 (online)
dc.identifier.other 10.1016/j.xcrm.2022.100510
dc.identifier.uri http://hdl.handle.net/2263/90658
dc.language.iso en en_US
dc.publisher Cell Press en_US
dc.rights © 2022 Authors. This is an open access article under the CC BY-NC-ND IGO license. en_US
dc.subject Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) en_US
dc.subject Vaccine en_US
dc.subject Antibodies en_US
dc.subject Infection en_US
dc.subject Variants of concern (VOCs) en_US
dc.title SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record